About The Company
15284
page-template,page-template-full_width,page-template-full_width-php,page,page-id-15284,cookies-not-set,ajax_fade,page_not_loaded,,qode-theme-ver-13.1.2,qode-theme-bridge,wpb-js-composer js-comp-ver-5.4.5,vc_responsive

About The Company

Our discoveries- FGF inhibitors

Dobecure arises in summer 2017 as a tool to lead to the market the investigation developed all over the years from its scientific board members with the FGF inhibitors.

Based on the preclinical and clinical investigations, developed since the late 80’s, it has been developed the registration dossier of the FGF inhibitors for the treatment of both presentation means (dry and wet) of age-related macular degeneration (AMD).

Moreover, Dobecure continues with the preclinical and clinical studies in other disorders where the FGF might be involved.

FGF inhibitors

Scientific Board

Dr. Pedro Cuevas

Dr. Pedro Cuevas Sánchez

Head of Investigation

Chair of Cardiology

Universidad Alfonso X el Sabio

Dr. Luis Outeriño

Dr. Luis Outeriño

Head of Ophtalmology Service

Hospital Pio XII

Prof. Guillermo Giménez

Prof. Guillermo Giménez Gallego

Research Professor

Biological Investigations Centre

CESIC. – Spain

Rocío García

Rocío García Cañamaque

Clinical Research Expert

Funder – LeónResearch

Management Board

Diego Cuevas

Diego Cuevas Bourdier

President

Dobecure, s.l.

Alfonso García

Alfonso García Cañamaque

CEO

Dobecure, s.l.

Objectives

Provide an effective and safe treatment for those diseases that can be treated with inhibitors of fibroblast growth factor (anti-FGF) particularly in the inflammation and angiogenesis processes.

Out-licence those inhibitors and the clinical results for a better distribution in the global market, while contributing to treat diseases associated with inflammation and angiogenesis which prevalence affects more than 500 million people worldwide.

Continue investigating in new potential clinical uses for the synthetic inhibitors of fibroblast growth factor (FGF)

Investigate to cure.

Strategy

HEALTH

Health

Our main challenge is the search for health.

TALENT

Talent

We need the talent of the people to reach all our challenges.

INTERNATIONALIZATION

Internacionalization

Our perspective is global, we want our research to have an international impact.

MARKET

Market

Despite limiting ours activity to research, we believe that the ultimate goal must be the market.